Table of contents

Clinical/translational cancer immunotherapy

• Original research: Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma (28 September, 2023)

  Chiara Brignole, Enzo Calarco, Veronica Bensa, Elena Giusto, Patrizia Perri, Eleonora Ciampi, Maria Valeria Corrias, Simonetta Astigiano, Michele Cilli, Derik Loo, Ezio Bonvini, Fabio Pastorino, Mirco Ponzoni
• Original research: Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR (21 September, 2023)

  Emily Maria Ploeg, Douwe Freerk Samplonius, Xiao Xiong, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Isabel Britsch, Anne Paulien van Wijngaarden, Hao Zhang, Wijnand Helfrich
• Original research: Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial (20 September, 2023)

  Wenwen Zhang, Shuang Tong, Bingyang Hu, Tao Wan, Haowen Tang, Feilong Zhao, Tianyu Jiao, Junfeng Li, Ze Zhang, Jinping Cai, Huiyi Ye, Zhanbo Wang, Shiqing Chen, Yafei Wang, Xuerui Li, Fangzhou Wang, Junning Cao, Lantian Tian, Xiaochen Zhao, Mingyi Chen, Hongguang Wang, Shouwang Cai, Minggen Hu, Yuezong Bai, Shichun Lu
• Original research: Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment (19 September, 2023)

  Lara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Sarah Lutzenberger, Michael Aigner, Patrick Philipp, Sebastian Robert, Beate Gandorfer, Dirk Hempel, Louisa Hempel, Dietmar Zehn
• Original research: CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity (19 September, 2023)

  Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Rui Li, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Tianhao Zhang, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul, Kostyantyn Krysan, Aaron E Lisberg, Edward B Garon, Bin Liu, Steven M Dubinett
• Original research:

  Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG

  (19 September, 2023)

  Maximilian Haist, Henner Stege, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Friedegund Meier, Peter Mohr, Katharina C Kähler, Michael Weichenthal, Axel Hauschild, Dirk Schadendorf, Selma Ugurel, Georg Lodde, Lisa Zimmer, Ralf Gutzmer, Dirk Debus, Bastian Schilling, Alexander Kreuter, Jens Ulrich, Frank Meiss, Rudolf Herbst, Andrea Forschner, Ulrike Leiter, Claudia Pfoehler, Martin Kaatz, Fabian Ziller, Jessica C Hassel, Michael Tronnier, Michael Sachse, Edgar Dippel, Patrick Terheyden, Carola Berking, Markus V Heppt, Felix Kiecker, Sebastian Haferkamp, Christoffer Gebhardt, Jan Christoph Simon, Stephan Grabbe, Carmen Loquai
• Original research: Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events (19 September, 2023)

  Karolina Gente, Leonore Diekmann, Lea Daniello, Julia Will, Manuel Feisst, Victor Olsavszky, Janine Günther, Hanns-Martin Lorenz, M Margarida Souto-Carneiro, Jessica C Hassel, Petros Christopoulos, Jan Leipe
• Original research: Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial) (13 September, 2023)

  Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo K Imamura, Sakiko Miura, Toshiko Yamochi, Hidetaka Kawabata, Hiroyuki Yasojima, Nobumoto Tomioka, Kenichi Yoshimura, Toshimi Takano
• Original research: Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis (7 September, 2023)

  Madeline Dahut, Kristen Fousek, Lucas A Horn, Shantel Angstadt, Haiyan Qin, Duane H Hamilton, Jeffrey Schlom, Claudia Palena
• Original research: Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis (7 September, 2023)

  Nian Liu, Mingjie Yan, Qian Tao, Jie Wu, Jing Chen, Xiang Chen, Cong Peng